![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
. | ![]() |
. |
![]() by Staff Writers Seoul (AFP) Oct 5, 2016
Samsung's drug-manufacturing unit plans to raise as much as $2.0 billion in November with what looks set to be South Korea's third-largest initial public offering (IPO). Samsung Biologics, a contract manufacturer of biotech drugs for global pharmaceutical firms, had announced the IPO plan back in April -- with parent Samsung Group seeking new growth engines as its key mobile phone business showed signs of topping out. According to the latest regulatory filing made by Samsung Biologics on Tuesday, the firm plans to offer 16.5 million shares at 113,000 to 136,000 won apiece, which could eventually raise up to 2.2 trillion won ($2 billion). "Samsung Biologics will use the proceeds to expand our manufacturing capacity and to further invest in research and development to aid in developing biomedicines," the firm said in the filing. "The proceeds will also be partly used to debt repayment to improve our financial structure," it said. Samsung aims to wrap up the public offering -- managed by a number of brokerages including J.P. Morgan and Credit Suisse -- by the end of this year. The firm was created in 2011 after Samsung Group announced a plan to invest 23 trillion won in healthcare and green energy over the next decade. It is currently owned by other sister firms Samsung C&T and Samsung Electronics. Samsung Biologics makes biopharmaceutical drugs for major firms including Bristol-Myers Squibb and Roche at plants west of Seoul. The firm has remained in the red for years as it invested heavily in its two existing plants and a new facility slated to open in 2018. The firm racked up a net loss of 75.7 billion won last year. jhw/gh/amu
Related Links Space Medicine Technology and Systems
|
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |